Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Breast Cancer, Gynecologic Cancer, Neck Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Thoracic Cancer, Cutaneous Tumor, Urologic Cancer, Neurologic Cancer, Lymphoma, Sarcoma, Bone Marrow Transplant
Interventions: Lay Navigation; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Lung Carcinoma
Interventions: Nicotine Replacement; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Vulvovaginal Atrophy
Interventions: no intervention; Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Colesevelam; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer, High-risk Prostate Cancer
Interventions: Darolutamide, Pembrolizumab, Lupron; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Carotid Stenosis
Interventions: carotid endarterectomy; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Leukemia, Myeloid, Acute
Interventions: BI 836858; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Prostate Cancer
Interventions: Leuprolide, Goserelin, Sunitinib Malate, Casodex, Radiation Therapy (RT); Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Interventions: Cyclophosphamide, Doxorubicin, Etoposide, Loncastuximab Tesirine, Prednisone, Rituximab, Vincristine; Drug · Biological
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Sacramento, California • San Diego, California

Conditions: Obesity Complicating Childbirth
Interventions: Neuraxial block placement; Procedure
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions: clofarabine, Ara-C; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 74 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression Mild, Depression, Depression Moderate
Interventions: Matter Neuroscience App, Stock Photos, No Home Training, Personal Photos, Home Training; Device · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Postoperative Nausea and Vomiting
Interventions: transdermal nicotine patch, placebo patch; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Mental Energy, Physical Performance
Interventions: Flavored beverage; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: AML, Adult, MDS, Relapse/Recurrence, Refractory Acute Myeloid Leukemia
Interventions: BST-236; Drug
Lead sponsor: BioSight Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Shreveport, Louisiana • Houston, Texas • Charlottesville, Virginia + 1 more

Conditions: Breast Cancer
Interventions: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 170
States / cities: Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 134 more

Conditions: Graft Versus Host Disease, Acute
Interventions: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Placebo, Corticosteroids; Biological · Drug
Lead sponsor: Cynata Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 9 more

Conditions: Prostate Cancer
Interventions: questionnaire administration, quality-of-life assessment, brachytherapy; Other · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertriglyceridemia
Interventions: Docosahexenoic acid (DHA), Olive oil; Dietary Supplement
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 39 Years to 66 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Davis, California

Conditions: Ovarian Cancer, Breast Cancer
Interventions: BKM120 and Olaparib, BYL719 and Olaparib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions: Ibrutinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Caregivers
Interventions: Cereset Research; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hematopoietic Stem Cell Transplantation, Cardiorespiratory Fitness
Interventions: High Intensity Interval Training; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Kansas City, Kansas • Durham, North Carolina • Houston, Texas

Conditions: Soft Tissue Sarcoma
Interventions: External Beam Radiation Therapy (RT), Autologous Dendritic Cells; Procedure · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida • Tampa, Florida

Search by objective public record fields.

Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study

Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer

High Tone Pelvic Floor Dysfunction

Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Study of Early Versus Delayed Carotid Endarterectomy (CEA) for Small to Medium-sized Ischemic Stroke Caused by High-grade Carotid Stenosis

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Ultrasound High BMI Study

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

fMRI Neurofeedback With Matter Neuroscience App

Transdermal Nicotine in Female Patients at High Risk for Post Operative Nausea and/or Vomiting (PONV)

Dose Effect of a Plant Extract on Fatigue

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

Internal Radiation Therapy in Treating Patients With Prostate Cancer

Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Cereset Research for Caregivers

Remotely Monitored, Mobile Health-supported, High Intensity Interval Training Before Hematopoietic Stem Cell Transplant

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)